FDA approval expands Guerbet’s gadopiclenol into neonates, reinforcing half-dose MRI contrast strategies. Find out what this changes for pediatric imaging.
Bracco Imaging S.p.A. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion supporting the use of Vueway gadopiclenol in pediatric patients from birth. The recommendation extends an existing European Union authorization and places the macrocyclic gadolinium-based contrast agent into one of the